Skip to main content

Medical Treatment of Fecal Incontinence

  • Chapter
  • 1040 Accesses

Abstract

Management of fecal incontinence (FI) should be based on a meticulous assessment of pathophysiology through both clinical and physiological diagnostic workup. There are cases with prevalently altered diet and hygiene. Very frequently, diarrhea and constipation can be found involved in the development and maintenance of FI [1-3], both in the presence or absence of other traumatic or nontraumatic causes. Consequently, in those cases, treatment must be directed toward cure of these dysfunctions, either as single-line or combined treatment. Little evidence exists in the available literature about medical therapy for FI; recently, a Cochrane Database Review high-lighted that “there is little evidence with which to assess the use of drug therapies for the management of fecal incontinence” [4]. Therefore, medical treatment in FI is debatable and often pragmatic.

Keywords

  • Irritable Bowel Syndrome
  • Chronic Diarrhea
  • Imperforate Anus
  • Celiac Sprue
  • Intestinal Peristalsis

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-88-470-0638-6_14
  • Chapter length: 3 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   189.00
Price excludes VAT (USA)
  • ISBN: 978-88-470-0638-6
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   249.99
Price excludes VAT (USA)
Hardcover Book
USD   249.99
Price excludes VAT (USA)

References

  1. Nelson R, Furner S, Jesudason V (1998) Fecal incontinence in Wisconsin nursing homes: prevalence and associations. Dis Colon Rectum 41:1226–1229

    PubMed  CrossRef  CAS  Google Scholar 

  2. Chassagne P, Landrin I, Neveu C et al (1999) Fecal incontinence in the institutionalized elderly: incidence, risk factors, and prognosis. Am J Med 106:185–190

    PubMed  CrossRef  CAS  Google Scholar 

  3. Levine MD (1975) Children with encopresis: A descriptive analysis. Pediatrics 56:412–416

    PubMed  CAS  Google Scholar 

  4. Cheetham M, Brazzelli M, Norton C et al (2003) Drug treatment for fecal incontinence in adults. Cochrane Database Syst Rev 4:1–26

    Google Scholar 

  5. Goode PS, Burgio KL, Halli AD et al (2005) Prevalence and correlates of fecal incontinence in communitydwelling older adults. J Am Geriatr Soc 53:629–635

    PubMed  CrossRef  Google Scholar 

  6. Drossman DA (1989) What can be done to control incontinence associated with irritable bowel syndrome? Am J Gastroenterol 84:365–366

    Google Scholar 

  7. Olden KW (2002) Diagnosis of irritable bowel syndrome. Gastroenterology 122:1701–1714

    PubMed  CrossRef  Google Scholar 

  8. Lembo TJ, Fink RN (2002) Clinical assessment of irritable bowel syndrome. J Clin Gastroenterol 35:S31–S36

    PubMed  CrossRef  Google Scholar 

  9. Fine KD, Meyer RL, Lee EL (1997) The prevalence and causes of chronic diarrhea in patients with celiac sprue treated with a gluten-free diet Gastroenterology 112:1830–1838

    CAS  Google Scholar 

  10. Bliss DZ, Jung HJ, Savok K et al (2001) Supplementation with dietary fiber improves fecal incontinence. Nurs Res 50:203–213

    PubMed  CrossRef  CAS  Google Scholar 

  11. Palmer KR, Corbett CL, Holdsworth CD (1980) Double-blind cross-over study comparing loperamide, codeine and diphenoxylate in the treatment of chronic diarrhea. Gastroenterology 79:1272–1275

    PubMed  CAS  Google Scholar 

  12. Read MG, Read NM, Duthie HL (1979) Effect of loperamide in anal sphincter function in patients with diarrhea. Gut 20:A942

    CrossRef  Google Scholar 

  13. Bergman L, Djarv L (1981) A comparative study of loperamide and diphenoxylate in the treatment of chronic diarrhoea caused by intestinal resection. Ann Clin Res 13:402–405

    PubMed  CAS  Google Scholar 

  14. Read M, Read NW, Barber DC et al (1982) Effects of loperamide on anal sphincter function in patients complaining of chronic diarrhea with fecal incontinence and urgency. Dig Dis Sci 27:807–814

    PubMed  CrossRef  CAS  Google Scholar 

  15. Hallgren T, Fasth S, Delbro DS et al (1994) Loperamide improves anal sphincter function and continence after restorative proctocolectomy. Dig Dis Sci 39:2612–2618

    PubMed  CrossRef  CAS  Google Scholar 

  16. Arnbjornsson E, Breland U, Kullendorff CM et al (1986) Effect of loperamide on faecal control after rectoplasty for high imperforate anus. Acta Chir Scand 152:215–216

    PubMed  CAS  Google Scholar 

  17. Carapeti EA, Kamm MA, Evans BK et al (1999) Topical phenylephrine increases anal sphincter resting pressure. Br J Surg 86:267–270

    PubMed  CrossRef  CAS  Google Scholar 

  18. Cheetham MJ, Kamm MA, Phillips RK (2001) Topical phenylephrine increases anal canal resting pressure in patients with faecal incontinence. Gut 48:356–359

    PubMed  CrossRef  CAS  Google Scholar 

  19. Ritchie JA, Truelove SC (1980) Comparison of various treatments for irritable bowel syndrome. Br Med J 281:1317–1319

    PubMed  CAS  CrossRef  Google Scholar 

  20. Farrar JT (1982) The effects of drugs on intestinal motility. Clin Gastroenterol 11:673–681

    PubMed  CAS  Google Scholar 

  21. Santoro GA, Eitan BZ, Pryde A et al (2000) Open study of low-dose amitriptyline in the treatment of patients with idiopathic fecal incontinence. Dis Colon Rectum 43:1676–1681

    PubMed  CrossRef  CAS  Google Scholar 

  22. Chassagne P, Jego A, Gloc P et al (2000) Does treatment of constipation improve faecal incontinence in institutionalized elderly patients? Age Ageing 29:159–164

    PubMed  CrossRef  CAS  Google Scholar 

  23. Prather CM, Camilleri M, Zinsmeister AR et al (2000) Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 118:463–468

    PubMed  CrossRef  CAS  Google Scholar 

  24. Tougas G, Snape WJ Jr, Otten MH et al (2002) Longterm safety of tegaserod in patients with constipationpredominant irritable bowel syndrome. Aliment Pharmacol Ther 16:1701–1708

    PubMed  CrossRef  CAS  Google Scholar 

Download references

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2007 Springer-Verlag Italia

About this chapter

Cite this chapter

Ratto, C., Parello, A., Donisi, L., Litta, F., Doglietto, G.B. (2007). Medical Treatment of Fecal Incontinence. In: Ratto, C., Doglietto, G.B., Lowry, A.C., Påhlman, L., Romano, G. (eds) Fecal Incontinence. Springer, Milano. https://doi.org/10.1007/978-88-470-0638-6_14

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-0638-6_14

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-0637-9

  • Online ISBN: 978-88-470-0638-6

  • eBook Packages: MedicineMedicine (R0)